BioSpace News Archive

Millendo Therapeutics, Inc. (Nasdaq:MLND), a clinical stage biopharmaceutical company primarily focused on developing novel treatments for endocrine diseases with significant unmet needs, today provided a corporate update and reported financial results for the quarter ended March 31, 2020. “As we wind down activities related to the livoletide program, we have moved quickly to streamline costs and redeploy developme

AptarGroup, Inc. (NYSE: ATR), a global leader in drug delivery, consumer product dispensing and active packaging solutions, is seeking Emergency Use Authorization (EUA) from the German Federal Institute for Drugs and Medical Devices (BfArM) for a solution that allows for easy disinfecting of FFP2 filtering facepiece respirators (FFP2 masks).

Total Primary Care has become the first medical provider in Texas to secure and offer a COVID-19 antibody test approved by the US Food and Drug Administration (FDA) for EUA use.

Allied Corp. (“Allied” or the “Company”) (OTCQB: ALID), an international medical cannabis company focused on creating and providing targeted cannabinoid health solutions to address today’s medical issues is pleased to announce the appointment of Jim Smeeding, RPh, MBA, to the Company’s Board of Directors.

ico metrix , the world leader in software solutions for extracting clinically meaningful data from brain scans using artificial intelligence (AI), is proud to announce that Jennifer Young has joined as Chief Commercial Officer.

- Selected as a Poster of Distinction for presentation during Digestive Disease Week 2020 - Proved its efficacy with outstanding inhibition of gastric acid secretion and safety - Proactively targeting the anti-acid secretion agent market valued $37 billion

Trial meets primary safety and efficacy endpoints with low complication rates, 100% effective closure with next-generation stroke risk reduction technology for patients with non-valvular atrial fibrillation

Beroni Group (OTCQX: BNIGF; NSX: BTG) (“Beroni” or the “Company”), an international diversified biopharmaceutical enterprise focused on the research, development, innovation and commercialization of therapies and products for treatment of global diseases, is pleased to announce that its development of a medical solution using nanobody technology for the novel coronavirus (COVID-19), in collaboration with Tianjin University in China,

Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) and Mount Sinai Health System (" Mount Sinai ") have agreed to join forces in the investigation and development of an antibody cocktail (COVI-SHIELD™) to potentially treat COVID-19.

BTB Real Estate Investment Trust (TSX: BTB.UN) (“BTB” or the “REIT”) announced today that due to the COVID-19 pandemic and the governmental decree limiting gatherings, its annual meeting of unitholders (“the Meeting”) to will be held via webinar